5d ago
WUXI APPTEC - Overseas Regulatory Announcement - Other
WUXI APPTEC CO., LTD.*
Wuxi WuXi AppTec New Drug Development Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 2359)
Overseas regulatory announcement
This overseas regulatory announcement is made by the Company in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.
By order of the board of directors
Wuxi WuXi AppTec New Drug Development Co., Ltd.
Chairman
Dr. Li Ge
Hong Kong, September 29, 2026
As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.
*For identification only
Securities Code: 603259 Securities Abbreviation: WuXi AppTec Announcement Number: Lin 2026-040 Wuxi WuXi AppTec New Drug Development Co., Ltd.
Announcement of Resolutions of the First Extraordinary Shareholders Meeting of the Year
2026
The company and all members of the board of directors guarantee that there are no false records, misleading statements or major omissions in the announcement content, and assume legal responsibility for the authenticity, accuracy and completeness of its content.
Important content reminder:
Is there any veto resolution at this meeting: None
- Meeting convening and attendance
(1) Time of the shareholders’ meeting: September 29, 2026
(2) The shareholders’ meeting will be held at: Sheraton Shanghai Waigaoqiao Hotel, Shanghai Free Trade Pilot Zone Foundation
No. 28 Long Road
(3) Ordinary shareholders attending the meeting and their holdings:
- Number of shareholders and proxies attending the meeting 4,241, including: number of A-share shareholders
4,239
Number of shareholders of overseas listed foreign shares (H shares) 2 2. Total number of shares with voting rights held by shareholders attending the meeting (shares) 1,722,821,529, of which: total number of shares held by shareholders of A shares 1,407,622,288
Total number of shares held by shareholders of overseas listed foreign shares (H shares) 315,199,241 3. The number of voting shares held by shareholders attending the meeting accounted for the company’s voting shares
Proportion of the total number of shares (%) 57.3308 Among them: Proportion of shares held by A-share shareholders to the total number of shares (%) 46.8418
Proportion of shares held by shareholders of overseas listed foreign shares to total shares (%) 10.4890
(4) Whether the voting method complies with the provisions of the "Company Law" and the "Articles of Association", the status of the meeting, etc.
This meeting was convened by the company's board of directors. The meeting was voted by a combination of on-site voting and online voting, and was chaired by Chairman Dr. Ge Li. The convening, holding and voting of the meeting complied with the provisions of the Company Law and the Articles of Association.
(5) Attendance of company directors and board secretary
The company has 11 current directors and 11 people are present.
Ms. Han Min, Secretary of the Company’s Board of Directors and Company Secretary, Ms. Shi Ming, Chief Financial Officer, and Wu Haobo, Vice President
Scholars attended the meeting.
- Proposal review status
(1) Non-cumulative voting proposals
- Proposal Name: "Proposal on Reviewing the 2026 A-Share Employee Stock Ownership Plan (Draft) of Wuxi WuXi AppTec New Drug Development Co., Ltd." and its Summary
Review result: Passed
Voting status:
Agree Disagree Abstain
Shareholder Type Proportion Proportion Proportion Number of votes Number of votes Number of votes
(%) (%) (%)
A shares 1,388,653,839 98.6524 18,800,174 1.3356 168,275 0.0120 H shares 254,230,222 80.6570 60,850,917 19.3055 118,102 0.0375 Total common shares: 1,642,884,061 95.3601 79,651,091 4.6233 286,377 0.0166
- Proposal Name: "Proposal on the Review of the 2026 A-Share Employee Stock Ownership Plan Management Measures of Wuxi WuXi AppTec New Drug Development Co., Ltd."
Review result: Passed
Voting status:
Agree Disagree Abstain
Shareholder Type Proportion Proportion Proportion Number of votes Number of votes Number of votes
(%) (%) (%) A shares 1,388,647,539 98.6520 18,800,174 1.3356 174,575 0.0124 H shares 254,230,122 80.6570 60,850,917 19.3055 118,102 0.0375 Total common shares: 1,642,877,661 95.3597 79,651,091 4.6233 292,677 0.0170
- Proposal Name: "Proposal on Authorizing the Board of Directors to Handle Matters Related to the 2026 A-Share Employee Stock Ownership Plan"
Review result: Passed
Voting status:
Agree Disagree Abstain
Shareholder Type Proportion Proportion Proportion Number of votes Number of votes Number of votes
(%) (%) (%) A shares 1,388,644,439 98.6518 18,798,174 1.3355 179,675 0.0127 H shares 254,230,122 80.6570 60,850,917 19.3055 118,102 0.0375 Total common shares: 1,642,874,561 95.3595 79,649,091 4.6232 297,777 0.0173
- Proposal Name: "Proposal on Amending the Articles of Association"
Review result: Passed
Voting status:
Agree Disagree Abstain
Shareholder Type Proportion Proportion Proportion Number of votes Number of votes Number of votes
(%) (%) (%)
A shares 1,407,225,453 99.9718 250,160 0.0178 146,675 0.0104
H shares 315,042,339 99.9503 38,700 0.0123 118,102 0.0374
Total common shares: 1,722,267,792 99.9679 288,860 0.0168 264,777 0.0153
(2) When major matters are involved, the voting status of shareholders below 5%
- Non-cumulative voting proposals
Agree, object, abstain
case
Motion name Proportion Proportion Proportion Sequence Number of votes Number of votes Number of votes
(%) (%) (%) number
1 "About Review<
Wuxi Wuxi
German new drug development
Co., Ltd.
Company A in 2026 904,964,307 97.9470 18,800,174 2.0348 168,275 0.0182 employee shares
plan (grass
case)>and its excerpts
"Necessary Bill"
2 "About Review<
Wuxi Wuxi
904,958,007 97.9463 18,800,174 2.0348 174,575 0.0189 German new drug development
Co., Ltd.
Division 2026A
Employee Stock Ownership
Planning and Management Office
Law>Proposal》
3 "About authorization
Handled by the board of directors
A shares in 2026
904,954,907 97.9460 18,798,174 2.0346 179,675 0.0194Employee stock ownership plan
Planning related matters
motion"
(3) Explanation of relevant circumstances regarding voting on motions
According to the voting results, all resolutions reviewed at this shareholders’ meeting were passed.
The company has convened an extraordinary employee representative meeting to review and approve the "Wuxi WuXi AppTec New Drug Development Co., Ltd. 2026 A-share Employee Stock Ownership Plan (Draft)" and the "Wuxi WuXi AppTec New Drug Development Co., Ltd. 2026 A-Share Employee Stock Ownership Plan Management Measures" submitted for consideration at this shareholders' meeting. Representatives attending the meeting recognized the original design intention and implementation orientation of this employee stock ownership plan, and believed that the plan is an important measure for the company to deepen the co-construction and sharing between the company and employees, and to gather synergy for team development. It is in line with the company's long-term development interests and the legitimate rights and interests of all employees.
- Lawyer’s testimony
(1) Law firm witnessing this shareholder meeting: Guoco Law Firm (Shanghai)
Lawyers: Wang Wei, Gong Liwen
(2) Lawyer’s concluding comments:
The convening and holding procedures of the company's shareholders' meeting are in compliance with the relevant provisions of Chinese laws and regulations such as the Securities Law, the Company Law, the Rules of Shareholders' Meetings, and the Articles of Association. The qualifications of the personnel attending the on-site meeting are legal and valid, the qualifications of the convener are legal and valid, the voting procedures and voting results are legal and valid, and the resolutions formed by this shareholders' meeting are legal and valid.
Announcement is hereby made.
Board of Directors of Wuxi WuXi AppTec New Drug Development Co., Ltd.
September 30, 2026